Aclaris Therapeutics, Inc. (ACRS)
Nasdaq · Healthcare · Biotechnology
$4.27−2.73%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $629M
- 52-week range
- $1.74 – $6.60
- 52-week change
- +138.59%
- EPS (trailing)
- −$0.58
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $7.8M (−58.19%)
- Net income
- −$64.9M
- Operating margin
- −975.9%
- Diluted EPS
- −$0.53
- Free cash flow
- −$47.2M
From the company’s annual report on SEC EDGAR.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc.
Headquarters: Wayne, United States · 69 employees · aclaristx.com